{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:59Z","timestamp":1788391199535,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.024","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"719-730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness and the Economics of Genomic Testing and Molecularly Matched Therapies"],"prefix":"10.1016","volume":"40","author":[{"given":"Sudeep","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.hoc.2026.05.024_bib1","doi-asserted-by":"crossref","first-page":"e2138793","DOI":"10.1001\/jamanetworkopen.2021.38793","article-title":"Anticancer drugs approved by the us food and drug administration from 2009 to 2020 according to their mechanism of action","volume":"4","author":"Olivier","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.024_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.024_bib3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended consequences of expensive cancer therapeutics - the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the john conley lecture","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol - Head Neck Surg"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.024_bib4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.024_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2026.05.024_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00002","article-title":"Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD anderson precision medicine study","volume":"1","author":"Tsimberidou","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.024_bib7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2026.05.024_bib8","unstructured":"Institute for Clinical Research and Health Policy Studies. Tufts Medical Center. Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry."},{"issue":"4","key":"10.1016\/j.hoc.2026.05.024_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jval.2020.10.008","article-title":"Cost-effectiveness analysis of a pharmacist-led medication therapy management program: hypertension management","volume":"24","author":"Schultz","year":"2021","journal-title":"Value Heal"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.024_bib10","doi-asserted-by":"crossref","first-page":"e2033761","DOI":"10.1001\/jamanetworkopen.2020.33761","article-title":"Cost-effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma","volume":"4","author":"Chiang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.024_bib11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1200\/JCO.22.00478","volume":"41","author":"Vijenthira","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.024_bib12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaoncol.2018.1395","article-title":"Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer","volume":"4","author":"Aguiar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.024_bib13","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2014.58.4904","article-title":"First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer:a United States-based cost-effectiveness analysis","volume":"33","author":"Goldstein","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.hoc.2026.05.024_bib14","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1200\/JCO.2015.61.9569","article-title":"Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer","volume":"33","author":"Goldstein","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.024_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2015.62.9105","article-title":"Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"34","author":"Durkee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.024_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrg.2017.108","article-title":"Cost-effectiveness analyses of genetic and genomic diagnostic tests","volume":"19","author":"Payne","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.hoc.2026.05.024_bib17","article-title":"Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non\u2013small-cell lung cancer from the perspective of spanish reference centers","volume":"7","author":"Arriola","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.hoc.2026.05.024_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00356","article-title":"Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non\u2013small-cell lung cancer using a decision analytic model","volume":"3","author":"Pennell","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.024_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2018.9824","article-title":"Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting","volume":"320","author":"Presley","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.024_bib20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jval.2021.09.017","article-title":"Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma","volume":"25","author":"Dong","year":"2022","journal-title":"Value Heal"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.024_bib21","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1245\/s10434-021-10288-4","article-title":"Cost-effectiveness analysis of adjuvant therapy for BRAF-mutant resected stage III melanoma in medicare patients","volume":"28","author":"Mojtahed","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.024_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ygyno.2016.04.024","article-title":"A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy","volume":"142","author":"Wallbillich","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.024_bib23","doi-asserted-by":"crossref","first-page":"e2013565","DOI":"10.1001\/jamanetworkopen.2020.13565","article-title":"Cost-effectiveness analysis of genetic testing and tailored first-line therapy for patients with metastatic gastrointestinal stromal tumors","volume":"3","author":"Banerjee","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"23","key":"10.1016\/j.hoc.2026.05.024_bib24","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/jnci\/djs433","article-title":"Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer","volume":"104","author":"Behl","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.024_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jval.2019.07.009","article-title":"Cost-effectiveness of RAS genetic testing strategies in patients with metastatic colorectal cancer: a systematic review","volume":"23","author":"Unim","year":"2020","journal-title":"Value Health"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.024_bib26","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1158\/1078-0432.CCR-10-2267","article-title":"KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective","volume":"17","author":"Blank","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.024_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF03256395","article-title":"Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer","volume":"14","author":"Shiroiwa","year":"2010","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.024_bib28","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ijc.26400","article-title":"Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany","volume":"131","author":"Vijayaraghavan","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2026.05.024_bib29","unstructured":"Medical Advisory Secretariat. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. Vol 10.; 2010. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23074403%0Ahttp:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=PMC3377508."},{"issue":"3","key":"10.1016\/j.hoc.2026.05.024_bib30","doi-asserted-by":"crossref","first-page":"e1919963","DOI":"10.1001\/jamanetworkopen.2019.19963","article-title":"Cost-effectiveness Evaluation of Targeted Surgical and Endoscopic Therapies for Early Colorectal Adenocarcinoma Based on Biomarker Profiles","volume":"3","author":"Jang","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.hoc.2026.05.024_bib31","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2014.59.3665","article-title":"Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis","volume":"33","author":"Gallego","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.024_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.surg.2020.06.038","article-title":"Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer","volume":"169","author":"Krepline","year":"2021","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.024_bib33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.6004\/jnccn.2014.0063","article-title":"NCCN guidelines updates: pancreatic cancer","volume":"17","author":"Tempero","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.024_bib34","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast cancer","volume":"5","author":"Manchanda","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.024_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: Origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.024_bib36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JOP.2016.019737","article-title":"Journey of generic imatinib: a case study in oncology drug pricing","volume":"13","author":"Chen","year":"2017","journal-title":"J Oncol Pract"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.024_bib37","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.024_bib38","first-page":"1","article-title":"Precision medicine: affording the successes of science","volume":"7","author":"Lu","year":"2023","journal-title":"npj Precis Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:02:26Z","timestamp":1788390146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000663"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.024","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness and the Economics of Genomic Testing and Molecularly Matched Therapies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}